...
首页> 外文期刊>Przegld Menopauzalny: Menopause Review >The influence of 17b-estradiol and norethisterone acetate given transdermally and low doses of acetylsalicylic acid on some selected parameters of coagulation and fibrinolysis in menopausal women with some risk factors for coronary heart disease
【24h】

The influence of 17b-estradiol and norethisterone acetate given transdermally and low doses of acetylsalicylic acid on some selected parameters of coagulation and fibrinolysis in menopausal women with some risk factors for coronary heart disease

机译:透皮给予17b-雌二醇和乙酸炔诺酮和低剂量乙酰水杨酸对具有冠心病某些危险因素的更年期妇女凝血和纤溶的某些选定参数的影响

获取原文

摘要

Aim of study: 1) The impact of transdermal hormone therapy (tHT) on coagulation and fibrinolysis of menopausal women with risk factors for coronary heart disease (CHD). 2) The usefulness of combining this therapy with some anti-thrombotic prophylaxis (low doses of acetylsalicylic acid - ASA). Material and methods: The study group – menopausal women (with 2 or more CHD risk factors) in which tHT composed of 17b-estradiol and NETA (G1, n=22) or the above tHT combined with low ASA doses were administered (ASA) (n=23). Controls were 16 premenopausal women. The following parameters were measured: prothrombin time and index, INR, thrombin time, APTT, fibrinogen, factor VII, vWF, AT III, protein C and S, PAI-1, t-PA, u-PA, TAFI, D-dimers. Treatment duration - 3 months. Results: The therapy influenced mainly some fibrinolytic parameters: in G1 a decrease of PAI-1 from 89.96±52.23 ng/ml to 68.04±31.54 ng/ml (p Conclusions: 1) Three months of tHT in menopausal women with some CHD risk factors influenced their fibrinolysis in a complex way. 2) It is not advisable to give low ASA doses as anti-thrombotic prophylaxis for this type of hormone therapy.
机译:研究目的:1)透皮激素疗法(tHT)对具有冠心病(CHD)危险因素的更年期妇女的凝血和纤维蛋白溶解的影响。 2)将该疗法与一些抗血栓形成预防措施(低剂量的乙酰水杨酸-ASA)相结合的有用性。材料和方法:研究组–绝经期妇女(患有2种或2种以上冠心病危险因素),其中服用由17b-雌二醇和NETA组成的tHT(G1,n = 22)或上述tHT并加低ASA剂量(ASA) (n = 23)。对照是16名绝经前妇女。测量以下参数:凝血酶原时间和指数,INR,凝血酶时间,APTT,纤维蛋白原,因子VII,vWF,AT III,蛋白C和S,PAI-1,t-PA,u-PA,TAFI,D-二聚体。治疗时间-3个月。结果:该疗法主要影响一些纤维蛋白溶解参数:在G1中,PAI-1从89.96±52.23 ng / ml降低至68.04±31.54 ng / ml(p结论:1)具有某些CHD危险因素的更年期妇女tHT三个月影响他们的纤维蛋白溶解的复杂方式。 2)不建议使用低剂量的ASA作为这种激素疗法的抗血栓形成预防措施。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号